Morphine is one of several opioids used to treat chronic pain. Because of its high abuse potential, urine drug tests can confirm "consistency with prescribed medications." Hydromorphone is a recently described minor metabolite of morphine, but few data exist on the characteristics of this metabolic pathway or the relationship of morphine and hydromorphone between and within subjects. Part I of this retrospective study shows that formation of hydromorphone from morphine is concentration-dependent and possibly saturated at high concentrations of morphine. In addition, the percentage of ultra-rapid metabolizers and poor metabolizers can be determined using the lower asymptote of a sigmoidal mathematical fit and are estimated to be 0.63 and 4.0%, respectively. Expected limits of morphine and hydromorphone (as a result of morphine metabolism) concentrations in the urine were established. Part II of this study used the metabolic ratio (hydromorphone -morphine) to determine the inter-patient and intra-patient variability in morphine metabolism to hydromorphone. Metabolic ratio values varied over a large range; 25-fold and 7-fold, respectively. The expected limits established in this study can assist in assessing the cause for possible variances in metabolism, such as drug interactions. The wide variability between and within subjects may explain unpredictable, adverse effects.
Introduction
Health care professionals have long recognized the potential for addiction and abuse of prescription opioids. In the past decade, a greater focus has been placed on pain management, which has led to a significant increase in the number of opioids prescribed and may have contributed to long-standing trends of abuse and addiction. A dichotomy exists in the realm of pain management between balancing the under-treatment of pain and the potential for opioid misuse. Opioids like morphine are a concern in the pain patient population because of their potential for harm. Between 2000 and 2009, the number of extended release morphine prescriptions alone increased 22% to approximately 4 million (1) . Furthermore, the Drug Abuse Warning Network (DAWN) reported an increase in the rate of emergency department visits due to morphine from 7.3 to 17.7 per 100,000 people from 2004 to 2009 (2) . Urine drug testing (UDT) is one of the tools that clinicians can use to monitor "medication taking behaviors" and avoid morbidity and mortality associated with opioids (3) . The use of liquid chromatography-tandem mass spectrometry (LC -MS-MS) in routine clinical analyses has allowed better interpretation of UDTs (4 -5).
Morphine is a pure opioid agonist widely used for acute and chronic pain. It is primarily metabolized to its glucuronide conjugates, morphine-3-glucuronide (M3G, 45-55%) and morphine-6-glucuronide (M6G, 10-15%) and excreted in the urine (6) . Hydromorphone has been recognized as a minor metabolite of morphine for more than five years. Evidence of hydromorphone as a minor metabolite of morphine was first described in a study conducted by Cone and colleagues, in which patients on highdose morphine were excreting trace amounts of hydromorphone in their urine (7) . The pathway that catalyzes the conversion of morphine to hydromorphone has not yet been characterized. One hypothesis is that morphine is converted to an intermediate, morphinone, by morphine dehydrogenase, and then morphinone is converted to hydromorphone via morphinone reductase (7) (8) .
With the ever-increasing amount of opioid-related adverse events and recent knowledge of the morphine pathway to hydromorphone, further study of the characteristics of morphine metabolism is warranted. Understanding the variability of this pathway among individuals may lead to better prediction of efficacy or toxicity. Few data exist on the inter-patient and intrapatient variability of morphine metabolism to hydromorphone. Establishing expected limits of morphine and hydromorphone (as a result of morphine metabolism) concentrations in the urine can be applied in several ways. First, the data can be used as an aid in interpreting drug screens for "medication monitoring." Second, in the clinical setting, it can assist physicians in detecting possible variances in metabolism caused by drug interactions. Finally, it can potentially help determine whether the formation of significant amounts of hydromorphone is aiding in the analgesic effect. The pain patient population is somewhat unique in that patients are tested frequently. This offers the opportunity to determine the intra-subject variability of metabolism and possibly shed some light on why so much morbidity and mortality are observed in patients on chronic opioid therapy (9) .
Experimental
Institutional Review Board-exempt status was granted by the University of California-San Diego Human Research Protection Program. All study data were de-identified, and the study dataset included a study-specific patient identification number, list of medications, and urine concentrations of creatinine, morphine and hydromorphone. This retrospective study was conducted to determine the relationship between morphine and hydromorphone concentrations in the urine and to examine inter-subject and intra-subject variability in metabolism.
Subjects and specimens Subjects were selected from a database containing urinary excretion data from pain patients. Selection criteria were based on specimen validity as defined by a creatinine concentration !20 mg/dL (10), physician's report of prescribing morphine, and absence of an interfering opioid (hydrocodone, hydromorphone, codeine and 6-acetylmorphine) as reported by the physician and verified by UDT results.
Screening and confirmation procedure Random urine samples were collected from pain patients undergoing routine clinical testing from March 2008 to February 2010. Quantitation of morphine and hydromorphone concentrations was conducted by Millennium Laboratories using a standard LC-MS-MS opioid targeted panel.
The analytical methods used in this study have previously been described (4) (5) 11) . Briefly, an Agilent 1200 Series Binary Pump SL Liquid Chromatography system, well plate sampler, thermostatted column compartment, paired with an Agilent 6410 triple quadrupole (QQQ) mass spectrometer and Agilent MassHunter software was used for analysis of all drugs. Chromatographic separation was performed using a gradient comprising 0.1% formic acid in water (mobile phase A) and 0.1% formic acid in acetonitrile (mobile phase B). A 2.1 Â 50 mm 2 , 1.8 mm Zorbax SB C18 column was used. The flow rate was 0.4 mL/min, and the column temperature was 508C. HPLC grade water, acetonitrile, methanol and formic acid were obtained from VWR (Westchester, PA).
Samples were prepared for injection by incubating 25 mL of urine with 50 units of b-glucuronidase Type L-II from Patella vulgata (keyhole limpet) (Sigma-Aldrich, St. Louis, MO), in 50 mL 0.4M acetate buffer (pH 4.5) for 2 h at 608C. Five microliters of sample were injected using a CT-PAL HTS (CTC Analytics AG, Switzerland). The carryover for this device was less than 0.01%.
The QQQ was used in positive electrospray ionization (ESI) mode. The instrument was set to the following optimized parameters: drying gas temperature, 3508C; gas flow, 12 L/min; nebulizer gas (nitrogen), 40 psi; capillary voltage, 3,000 V; dwell time, 50 milliseconds. Data were acquired running the QQQ in multiple reaction monitoring (MRM) mode, using transitions morphine-D6: 292. Calibrators of either 1,000 or 100 mg/mL and deuterated internal standards 100 mg/mL in methanol were obtained from Cerilliant (Round Rock, TX). The deuterated internal standards were diluted to 1000 ng/mL by adding them to synthetic urine (Microgenics Corp., Fremont, CA). Upper limits of linearity were determined for all of the analytes by dilution of the Cerilliant certified standards into synthetic urine (Microgenics negative control). Ion suppression was corrected by use of the deuterated internal standards. The efficiency of the hydrolysis procedure was determined by use of a morphine glucuronide control. Hydrolysis of the control material was considered acceptable if the value of the recovered morphine was above 90% of the nominal concentration.
Quantitative analysis was performed using Agilent MassHunter software. A four-point calibration curve was created using morphine concentrations of 50, 500, 3,200 and 6,400 ng/mL and forcing a linear fit through the origin. A value !0.95 was required for the correlation coefficient (R 2 ) as verification of linearity and best fit. The lower limits of quantitation (LLOQ) for the morphine and hydromorphone assays were 50 ng/mL. The measured upper limits of linearity for the morphine and hydromorphone assays were 500,000 ng/mL and 100,000 ng/mL, respectively. Concentrations greater than the upper limit of linearity were estimated using linear regression extrapolation from concentrations less than the upper limit of linearity. This represented only eight specimens (0.17%). Creatinine was measured using Jaffe's method (picric acid) with reagents obtained from Microgenics Corporation (DRI Creatinine -Detect-Test) and a linear range of 0.21 to 350 mg/dL.
Calculations, statistical methods and graphical analyses For this study, results greater than the LLOQ for each analyte, 50 ng/mL for both morphine and hydromorphone, were considered positive. Values greater than the upper limit of quantitation were extrapolated. The laboratory information system was that of Millennium Laboratories (San Diego, CA), which downloaded the instrument information into a Microsoft Excel database.
Subjects who met the inclusion criteria were selected for analysis based on the LLOQ of the assay and number of visits. All subjects with morphine and hydromorphone concentrations !50 ng/mL were categorized as the inter-subject population for single or first visit results. The intra-subject population is a subpopulation and includes subjects with five or more visits. The metabolic ratio was calculated for those subjects that demonstrated both morphine and hydromorphone concentrations of !50 ng/mL as the ratio of hydromorphone to morphine. This value is the best estimate of morphine metabolism to hydromorphone in the absence of dosage information. Morphine and hydromorphone concentrations, initially in ng/mL, were normalized using the creatinine concentration to account for subject variability due to muscle mass and hydration status. The final corrected value was expressed in milligrams per gram of creatinine, mg/g Cr (12) .
Descriptive statistics were calculated using Microsoft Excel 2007 (Microsoft Corp., Redmond, WA), and graphical analyses and statistical tests were performed using OriginPro 8.1 (OriginLab, Northampton, MA). The creatinine corrected data and metabolic ratio (MR) were log-transformed to achieve a Gaussian distribution. Regarding the analysis of inter-subject and intra-subject variability, data are presented as geometric means (GM) and 95% confidence interval (CI) values (13) . Regarding intra-subject variability, for individuals with five or more visits (n ¼ 121), the MRs were averaged within a subject and those within-subject average values were used to determine the intrasubject GM and 95% CI. Outliers were not excluded when calculating descriptive statistics. The fold-difference in MR was calculated by dividing the highest MR by the lowest for each population. These fold-differences were compared to describe the differences in variability in the populations.
Linear regression analyses using the least squares method were performed using hydromorphone concentration, morphine concentration and metabolic ratio to determine correlation.
Observations on the Metabolism of Morphine to Hydromorphone in Pain Patients 251 Figure 1 summarizes the results of the selection process. Of 160,380 subjects, morphine use was reported and verified for 9% (14,448/160,380) of subjects. With reported morphine use, 58% (8,442/14,448) took an interfering opioid. The intersubject population (N ¼ 4,650) was selected from 7,516 single and first visit results. Sixty-two percent (4,650/7,516) of these subjects had morphine and hydromorphone !50 ng/mL. The intra-subject population was selected from 4,969 subjects with morphine and hydromorphone !50 ng/mL. Approximately 4% (121/4,969) had five or more visits. The number of visits in the intrasubject population ranged from five to 13 visits. There were 47 subjects with five visits, 37 with six visits, 13 with seven visits, seven with eight visits, five with nine visits, five with 10 visits, three with 11 visits, three with 12 visits, and one with 13 visits. For this study, eight results for morphine concentration exceeded its upper limit of linearity (.500,000 ng/ mL), while none of the hydromorphone results exceeded the upper limit of linearity of 100,000 ng/mL. Morphine concentrations .500,000 ng/mL were estimated using linear regression extrapolation from concentrations ,500,000 ng/mL.
Results

Population selection
Inter-subject population metabolism Descriptive statistics for morphine concentration, hydromorphone concentration and MR (hydromorphone/morphine) are presented as back-transformed and log-transformed values in Table I and their respective histograms are presented in Figures 2 -4A . The log-transformed frequency distributions for morphine, hydromorphone and MR approximated a Gaussian distribution. The GM morphine concentration was 26 mg/g Cr (95% CI: 25-27) and ranged from 3 to 249 mg/g Cr in 95% of the population. The GM hydromorphone concentration was 0.20 (95%: 0.19 -0.20) and ranged from 0.03 to 1.49 mg/g Cr in 95% of the population. The metabolic ratio was 0.008 (95% Figure 1 . Subject selection. The inter-subject population was selected from single and first visit results with morphine and hydromorphone concentration !50 ng/mL. The intra-subject population included subjects with morphine and hydromorphone concentration !50 ng/mL with five or more visits. CI: 0.007 -0.008) and ranged from 0.001 to 0.04 (40-fold range) in 95% of the population. Enclosing 95% of the population defines the upper and lower 95% confidence limits of the expected urine morphine and hydromorphone concentrations in the pain patient population. Linear regression analysis was used to determine the relationships between morphine, hydromorphone and MR. A positive correlation (y ¼ 0.6240x -1.5857, R 2 ¼ 0.49) was observed between morphine and hydromorphone concentration ( Figure 5) . A negative correlation (y ¼ 0.3760x -1.5857, R 2 ¼ 0.26) was observed between the metabolic ratio and morphine concentration. Although morphine conversion to hydromorphone shows a positive linear relationship, there is not a proportional, one-to-one relationship between morphine and hydromorphone ( Figure 6A ). The metabolic ratios corresponding to values surrounding the median morphine concentration (1.45 + 0.10) were examined in Figure 6B . This histogram differs from Figure 4A in that only a narrow range of morphine concentrations is included. Like the population at large, these metabolic ratios approximate a Gaussian distribution.
Intra-subject population metabolism
Descriptive statistics for morphine concentration, hydromorphone concentration and MR are presented as backtransformed and log-transformed values for the intra-subject population in Table II . The GM morphine concentration was 36 mg/g Cr (95% CI: 35-38) and ranged from 7 to 188 mg/g Cr in 95% of the population. The GM hydromorphone concentration was 0.27 (95%: 0.26 -0.28) and ranged from 0.06 to 1.29 mg/g Cr in 95% of the population. The metabolic ratio Figure 4 . Metabolic ratio histograms. This histogram represents the distribution of the metabolic ratio in the inter-subject population (N ¼ 4,650) . The 95% confidence limits of the inter-subject population range 40-fold (A). This histogram represents the distribution of the metabolic ratio in the intra-subject population (N ¼ 121). The 95% confidence limits of the intra-subject population range 7-fold (B). was 0.007 (95% CI: 0.007 -0.008) and ranged from 0.003 to 0.02 (7-fold range) in 95% of the population. The distribution of the intra-subject population metabolic ratio is shown in Figure 4B .
Line graphs of the subjects with the highest (1.03), median (0.18) and lowest (0.06) log standard deviation (SD) of the MR are presented in Figure 7 to provide a closer look in the change in variability in morphine metabolism from visit to visit. For the subject with the highest variability, fluctuation is apparent in the MR from visit to visit, which can be attributed to the changes in morphine concentration. For the other two subjects, the metabolic ratios are relatively constant, as are the morphine and hydromorphone concentrations.
Comparison of the inter-subject and intra-subject population A comparison of the two populations shows that the intersubject variability (40-fold range) is greater than the intrasubject variability (7-fold range). A summary of this comparison is presented in Table III and histograms showing the intersubject and intra-subject population metabolic ratio distributions are in Figures 4A-B .
Discussion
Expected limits for morphine and hydromorphone urine concentration The excretion histograms and the tabulated data (Figures 2-4A and Table I ) provide a range of expected values in the pain patient population for practitioners interpreting urinary excretion data for morphine and hydromorphone (as a result of morphine metabolism). Interestingly, the log transformation of the data approximates a Gaussian distribution. The average population urine morphine concentration in this study, 26 mg/g Cr, is comparable to theoretical estimates of the expected urine morphine concentrations using typical excretion percentages for morphine and creatinine. Assuming that an average oral daily dose of morphine is 180 mg/day (6), an oral bioavailability of 40% (6), morphine and glucuronide conjugate excretion of 80% (10% morphine unchanged, 55% M3G, 15% M6G) (6), and creatinine excretion of 2 g/ day (14) , the theoretical urine morphine concentration is 29 mg/ g Cr (180 mg/day Â 0.4 Â 0.8 4 2 g Cr/day). This demonstrates that the limits obtained from this patient population are within reason and may be relevant and applicable in a clinical setting.
Relationships between morphine, hydromophone and metabolic ratio Our results demonstrate a positive correlation between morphine and hydromorphone concentrations, as shown in Figure 5 . However, the relationship is not directly proportional, possibly due to saturation in metabolism or urinary excretion.
This observation agrees with previous studies conducted by Cone and colleagues relating morphine and hydromorphone concentrations, R 2 ¼ 0.36 (15) . A negative relationship is observed between morphine concentration and the MR (hydromorphone/morphine), as shown in Figure 6A . As the concentration of morphine increases, the metabolic ratio decreases, further supporting the possibility of a saturated metabolic pathway. The variance in the metabolic ratio around the median morphine concentration is 16-fold and approximates a Gaussian distribution. This demonstrates an inherent variability in the metabolism of morphine to hydromorphone independent of dose. Variability in metabolism can be attributed to many factors, including pharmacogenetic variability of the metabolizing enzyme or by irregular dose administration.
Inter-subject and intra-subject variability Our research is novel on the concept of inter-subject and intrasubject variability of the metabolism of morphine to hydromorphone. The range of both the inter-subject and intra-subject MR values is large, 40-fold and 7-fold, respectively; however, the values support observations in the pioneering studies (Table IV) conducted by other investigators (7, 15, 16 -18) . A case study conducted by Reisfield and colleagues (16) showed an MR as low as 0.0006, while the studies conducted by Cone and colleagues show an MR as high as 0.024 (7) . The large population is a strength of this study. As a result, a clearer picture of the expected values for MR is established. These findings may allow physicians to detect metabolic changes that significantly deviate from what is expected. 
Limitations
The laboratory was not able to measure the major metabolites for morphine, including M6G or M3G, and hydromorphone due to hydrolysis by b-glucuronidase. Detection of adulteration may be possible by doing a substractive measurement (i.e., preand post-glucuronidase treatment). Additionally, the dosage of drug given to the patient is unknown; therefore, the variance in MR could be due to differing doses. The variance in the MR was calculated from a narrow range of excreted morphine as an attempt to correct for this limitation. A slice of the range of values around the median log morphine concentration (1.35 to 1.55) in Figure 6A was used. The distribution of the corresponding metabolic ratios was Gaussian ( Figure 6B ), and the variance of the values was 16-fold. This demonstrated that the variance in MR is not a result of differing doses alone; more than likely, varying doses contributed minimally to the wide range in metabolism. This study is retrospective and no data were collected with regard to collection time after last dose, age, gender and ethnicity. However, these types of spot urine tests are used to establish "consistency" with opioid medication treatment plans, often involving morphine.
Conclusion
These data are consistent with concentration dependent metabolism of morphine to hydromorphone; however, there is also the possibility that the metabolism of hydromorphone may be impaired or accelerated. A wide variability in morphine metabolism to hydromorphone was observed both between subjects and within subjects, which can be explained by a number of factors, including possible polymorphisms in the enzyme responsible for converting morphine to hydromorphone. Because the enzyme is unknown, no reliable conclusions regarding metabolic status (i.e., poor or ultra-rapid metabolism) can be drawn for subjects in this population. However, for practitioners interpreting urine drug screens, knowing the expected limits of hydromorphone in the urine and its relationship to the observed morphine concentration is helpful. 
